Welcome to our dedicated page for ASP Isotopes SEC filings (Ticker: ASPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ASP Isotopes Inc. (NASDAQ: ASPI) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on ASP Isotopes’ activities as a development stage advanced materials company focused on isotope enrichment technologies, as well as the work of its subsidiaries in nuclear fuels, helium, and related areas.
Through current reports on Form 8-K, ASP Isotopes discloses material events such as the closing of its acquisition of Renergen Limited, a helium and liquefied natural gas producer with operations at the Virginia Gas Project in South Africa. Other 8-K filings describe regulatory approvals for that transaction, private placements of convertible notes issued by its subsidiary Quantum Leap Energy LLC to fund laser enrichment production facilities, and confidential submission of a draft registration statement for a proposed initial public offering of Quantum Leap Energy’s Class A common stock.
The company’s 8-K filings also cover regulatory engagement in the United Kingdom by Quantum Leap Energy Ltd regarding potential High-Assay Low Enriched Uranium (HALEU) production, as well as the acquisition of assets from One 30 Seven Inc. to develop Creber Units for processing water-soluble nuclear waste. These documents provide formal descriptions of transaction terms, use of proceeds, conversion mechanics for notes, and related risk and disclosure language.
ASP Isotopes’ definitive proxy statement on Schedule 14A outlines governance matters, including the annual meeting agenda, director elections, auditor ratification, and voting procedures. The proxy materials also describe the company’s status as an emerging growth company and provide information on its capital structure and shareholder voting rights.
On Stock Titan, investors can use AI-powered tools to read summaries of these filings, quickly identify key sections, and navigate to specific topics such as capital raises, acquisitions, nuclear fuel cycle initiatives, or governance changes. Real-time updates from EDGAR ensure that new 8-Ks, proxy statements, and other relevant filings for ASPI are available as they are published, helping users follow how ASP Isotopes documents its strategic transactions, financing activities, and regulatory developments.
ASP Isotopes Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add Part III information on directors, executive officers, compensation, ownership and auditor fees. The amendment does not update financial statements and should be read together with the original filing.
For 2025, CEO Paul Mann received total compensation of about $16.8 million, including salary, cash bonus and significant equity awards. The filing also discloses that non‑affiliate market value was approximately $399.8 million and that 125,903,447 common shares were outstanding as of April 29, 2026.
BlackRock, Inc. files an amended Schedule 13G reporting beneficial ownership of 8,274,763 shares of ASP Isotopes Inc. The amendment (Amendment No. 1) lists 8,274,763 shares beneficially owned, representing 6.6% of the class, with 8,117,277 shares of sole voting power and 8,274,763 shares of sole dispositive power. The cover shows a 03/31/2026 reference and the filing is signed on 04/27/2026. The filing states the holdings reflect aggregated positions of Reporting Business Units of BlackRock and notes various persons may have rights to dividends or proceeds but no other single person holds more than 5%.
ASP Isotopes Inc. COO Robert Ainscow reported an open-market sale of 22,500 shares of Common Stock at a weighted average price of $5.205 per share. According to the disclosure, this was a "sell to cover" transaction under a Rule 10b5-1 trading plan adopted on June 9, 2025 to cover tax withholding obligations tied to vesting restricted stock awards. After the sale, he directly held 1,490,317 shares, so the transaction represents a small portion of his overall position.
ASP Isotopes Inc. Chief Financial Officer Heather Kiessling reported an open-market sale of 23,124 shares of common stock on April 15, 2026 at a weighted average price of $5.478 per share. The footnotes state this was a "sell to cover" under a Rule 10b5-1 trading plan adopted on December 19, 2025 to cover tax withholding obligations tied to vesting restricted stock awards. After the sale, she directly holds 709,376 shares of ASP Isotopes common stock.
ASP Isotopes Inc. director Duncan Moore reported multiple stock transactions. He sold 11,642 shares of common stock at a weighted average price of $5.205 per share in an open-market trade. Following this sale, he directly owned 1,044,928 shares of ASP Isotopes common stock.
The filing also shows two earlier awards of restricted stock for his service as an independent director: 25,469 shares on November 12, 2025 and 36,548 shares on December 18, 2025, both granted at no cash cost. The sale on April 16, 2026 was executed under a Rule 10b5-1 trading plan adopted on December 31, 2025 and included shares sold to cover income tax liabilities from the vesting of a prior restricted stock award.
ASPI submitted a Form 144 notice regarding the potential sale of 25,469 shares of Common Stock. The shares were acquired as compensation (Restricted Stock Award) on 11/12/2025. The filing is dated 04/16/2026 and lists NASDAQ trading.
ASP Isotopes Inc. reported proposed and recent sales of Common Stock by an affiliate via a Form 144 disclosure. The filing shows a 400,000-share Restricted Stock Award acquired 04/14/2025 and two recent dispositions: 8,438 shares sold on 03/06/2026 for $45,894.28 and 25,000 shares sold on 04/13/2026 for $112,775.00.
The record lists these trades as equity compensation and brokered sales; the filing names Robert Ainscow as the selling contact. Timing and amounts are shown explicitly in the disclosure.
ASPI filed a Form 144 notice reporting proposed sales of Common Stock. The excerpt lists quantities including 231,240 and 23,124 tied to restricted stock awards and a larger figure 125,903,447 in the securities information row with date 04/15/2026.
ASP Isotopes Inc. COO Robert Ainscow reported an open‑market sale of 25,000 shares of common stock on March 6, 2026. The sale was executed at a weighted average price of $4.511 per share, with individual trades ranging from $4.42 to $4.58.
These sales were made under a pre‑arranged Rule 10b5-1 trading plan adopted on December 13, 2024, indicating they were scheduled in advance. Following this transaction, Ainscow directly holds 1,512,817 shares of ASP Isotopes common stock.
ASPI notice of proposed sale under Rule 144. A reporting person indicated a proposed sale of 300,000 shares of Common Stock that were acquired as a Restricted Stock Award on 09/06/2024. The filing also shows 8,438 shares sold in the past three months for $45,894.28. Shares outstanding are listed as 125,903,447 as of 04/13/2026.